The Oncology Institute (TOI) Q4 2025 earnings review
Milestone Reached: Positive Adjusted EBITDA as Pharmacy Scales
The Oncology Institute executed perfectly on its 'North Star' promise to investors, achieving its first-ever quarter of positive Adjusted EBITDA ($147K) in Q4. Revenue growth is accelerating, up 41.6% YoY to $142.0 million, fueled by a massive 71% surge in the Specialty Pharmacy segment and the rapid expansion of delegated capitation contracts. While net income remains negative, operating cash flow reversed to a positive $3.2 million for the quarter. Management set a confident tone for FY26, guiding for ~27% revenue growth and full-year positive Adjusted EBITDA, though Q1 will see a temporary seasonal dip.
🐂 Bull Case
Management promised positive Adjusted EBITDA by Q4 and delivered. Operating cash flow also turned positive ($3.2M), validating the financial viability of their value-based care model at scale.
Specialty Pharmacy revenue grew 71% YoY in Q4 to $81.4M. It is now the largest component of total revenue, driving significant gross profit dollar expansion and buffering against patient services volatility.
🐻 Bear Case
To fund operations and working capital during the cash-burn phase, TOI aggressively utilized at-the-market offerings. Outstanding shares ballooned from 75.7M at the end of 2024 to 98.9M by the end of 2025.
Despite Q4's operational progress, the FY26 guidance projects Free Cash Flow between $(15)M and $5M. Meaningful, sustained cash generation is still likely a 2027 story.
⚖️ Verdict: 🟢
Bullish. The company is successfully transitioning from a cash-burning growth story to a scaled, self-sustaining operation. Hitting the Q4 EBITDA target builds management credibility, and the FY26 growth guidance is robust.
Key Themes
Specialty Pharmacy Drives the Top Line
Accelerating. The Specialty Pharmacy segment has become TOI's primary growth engine. Q4 revenue hit $81.4M, up 71% YoY and up sequentially from $75.9M in Q3. This growth is driven by improved script attachment rates and the opening of new pharmacy locations. Management expects the segment to maintain a run-rate of ~$27M per month heading into 2026, plus 3-5% incremental growth from newly captured capitation lives.
Delegated Capitation Expansion
Accelerating. TOI initiated 9 new capitated contracts in 2025 across CA, FL, and NV, adding 260,000 covered lives. A massive catalyst is the ongoing expansion with Elevance in Florida, which is slated to more than double in 2026. Management explicitly targets $150M in capitated revenue for 2026. The fully delegated model allows TOI to control utilization and capture more margin compared to their legacy narrow networks.
Technology and AI Implementations Maturing
TOI is leveraging technology to drive SG&A leverage. Previous quarters highlighted 'agentic AI' cutting prior authorization times from 18 minutes to 5 seconds. In Q4, management announced the upcoming 2026 launch of a proprietary network provider portal designed to strengthen engagement and efficiency with affiliated MSO partners, which now span 146 clinics.
Q1 Seasonality & Drug Pricing Lags
Reversing. After celebrating positive EBITDA in Q4, management warned that Q1 2026 Adjusted EBITDA will temporarily revert to negative $(1)M to $(3)M. This is driven by annual patient deductible resets and a lag in reimbursement rate adjustments compared to immediate annual drug pricing increases. This seasonality will briefly interrupt the narrative of sequential profit expansion.
Clinical Trials Segment Effectively Eliminated
Decelerating. Revenue from Clinical Trials & Other collapsed to just $705K in Q4, down from $2.46M a year ago. This aligns with management's earlier strategic decision to outsource this business to Helios. While it removes a distraction, it places the entire burden of future growth on the Pharmacy and Capitation segments.
Macro Risk: Tariffs and Supply Chain
Management explicitly cited macroeconomic risks in their guidance disclaimer, noting that recent tariff rate increases and exchange rate volatility could negatively impact world trade. Given TOI's heavy reliance on specialty drug procurement, any tariff-driven inflation on pharmaceuticals or medical supplies could compress the delicate margins they have just begun to achieve.
Other KPIs
Accelerating. Gross margin improved from 14.1% in 24Q4 to 16.0% in 25Q4. Total gross profit dollars surged 55.2% YoY to $22.7M, vastly outpacing the 41.6% revenue growth. This demonstrates the superior margin profile of their maturing delegated capitation contracts and increased scale in drug purchasing.
Reversing. A critical milestone. After burning $27.8M in operations during the first nine months of the year due to inventory and working capital needs, Q4 generated $3.2M in positive operating cash flow. Management credited 'disciplined working capital management'.
Decelerating (from an investor value perspective). The share count rose by roughly 23 million shares (+30%) YoY from 75.7M at the end of 2024. This massive dilution was the price paid via ATM offerings and private placements to bridge the company to cash flow positivity without violating debt covenants.
Guidance
Stable/Accelerating. The midpoint of $640M implies 27.3% YoY growth over FY25's $502.7M. This shows confidence that the massive growth spurt in 2025 wasn't a one-off, supported by the $150M baseline expected from capitation.
Accelerating. Moving from a $(12.4)M loss in FY25 to a positive $4.5M midpoint is a massive fundamental shift. This confirms that the Q4 milestone is viewed as the new normal run-rate, overcoming the guided $(1)M to $(3)M dip in Q1.
Stable. The midpoint of $(5)M indicates that while EBITDA is turning positive, working capital requirements for new contracts and pharmacy inventory will continue to consume cash. Investors should monitor if TOI needs to tap equity markets again.
Key Questions
Margin Profile of New Florida Lives
You are doubling your capitation partnership with Elevance in Florida. Given the typical 'continuity of care' margin drag on new contracts, how significantly will this weigh on patient services gross margin in the first half of 2026?
Path to Sustained Free Cash Flow
While Adjusted EBITDA is guided positive for FY26, the FCF midpoint is still negative $5 million. At what revenue run-rate or specific milestone do you expect working capital to normalize and FCF to turn consistently positive?
Tariff Risk Management
The guidance release specifically cited tariff rate increases as a potential negative impact. Can you quantify your exposure to imported medical supplies or pharmaceuticals, and what pricing power do you have to pass these costs through to payers?